1-(1H-indol-2-yl)-2-methylpropan-1-one | 1435944-07-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(1H-indol-2-yl)-2-methylpropan-1-one
• CAS: 1435944-07-2
• 化学式: C₁₂H₁₃NO
• 分子量: 187.241
• InChiKey: PWLKTHNYWDKZRW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  32.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N-(2-(bromomethyl)phenyl)-4-methyl-benzenesulfonamide 在 碘 、 sodium hydride 、 potassium carbonate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 mineral oil 为溶剂， 反应 2.5h， 生成 1-(1H-indol-2-yl)-2-methylpropan-1-one
  参考文献：
  名称：

  碘介导的酮类分子内胺化：通过调节N保护基团合成2-acylindoles和2-acylindoline。

  摘要：

  提出了通过I2介导的分子内CN键形成构建2-acylindoles和2-acylindolines的一般方法，并且2-acylindoles或2-acylindolines的选择性形成仅取决于在相同底物骨架中使用的氮保护基团。 。

  DOI：

  10.1039/c3cc40797g

文献信息

• AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS
  申请人：Rodgers James D.

  公开号：US20090233903A1

  公开（公告）日：2009-09-17

  The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及吲哚啉和环丁烷衍生物，以及它们的组合物、使用方法和制备方法，这些JAK抑制剂在治疗JAK相关疾病中很有用，包括炎症性和自身免疫性疾病，以及癌症。
• Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors
  申请人：Niu Deqiang

  公开号：US20070299078A1

  公开（公告）日：2007-12-27

  The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及化合物，包括式I的化合物，或其药用可接受的盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是丝氨酸蛋白酶活性，尤其是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还可用作抗病毒药剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• Quinoxalinyl tripeptide hepatitis C virus inhibitors
  申请人：Gai Yonghua

  公开号：US20080032936A1

  公开（公告）日：2008-02-07

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I的化合物，或其药用可接受的盐、酯或前药，其抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰了乙型肝炎病毒的生命周期，同时也可用作抗病毒药物。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给受试者投与含本发明化合物的药物组合物来治疗HCV感染的方法。
• IDENTIFICATION OF ANTI-CANCER COMPOUNDS AND COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE AND METHODS OF TREATMENT THEREOF
  申请人：Stockwell Brent R.

  公开号：US20100022637A1

  公开（公告）日：2010-01-28

  Small molecule screening via high-throughput screening (HTS) methods was employed to identify compounds useful for treating or preventing cancer (such as compounds that enable cells to overcome E6-oncoprotein-mediated drug resistance) or neurodegenerative disorders (such as Huntington's disease, HD). Compounds were identified that potentiate the lethality of anti-tumor agents as well as rescue a disease-state lethality. These compounds are acylated secondary amines referred to herein as indoxins and revertins.

  高通量筛选（HTS）方法通过小分子筛选，用于鉴定可用于治疗或预防癌症（例如使细胞克服E6致癌蛋白介导的药物耐药性的化合物）或神经退行性疾病（例如亨廷顿病，HD）的化合物。已鉴定出可增强抗肿瘤药物的致死性并挽救疾病状态致死性的化合物。这些化合物是称为indoxins和revertins的酰化次级胺。
• PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3252049A1

  公开（公告）日：2017-12-06

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式 (I) 的化合物： 或其立体异构体、同系物或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性 ROCK 抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物治疗心血管、平滑肌、肿瘤、神经病理、自身免疫、纤维化和/或炎症性疾病的方法。